Our finding is in accordance with the recent genome-wide association study across 1,240 Crohn’s disease patients enrolled in the PANTS (Personalizing anti-TNF Therapy in Crohn’s disease) cohort showing that HLA-DQA1*05 is significantly associated with an increased rate of ADAs in patients treated with infliximab and adalimumab [42]. The gene discussed is TNF; the disease is Crohn disease.